FDA approves LYNPARZA® (olaparib) in germline BRCA-mutated metastatic breast cancer
AstraZeneca and Merck announced the FDA has approved LYNPARZA® (olaparib) for use in patients with deleterious or suspected deleterious gBRCAm, HER2-negative metastatic breast cancer who have been previously treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. January 12, 2018